Metacrine, Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Metacrine, Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Metacrine, Inc. Competitors
Metacrine, Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans